AZN Stock Recent News
AZN LATEST HEADLINES
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations. The Food and Drug Ad.
Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism.
Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri as Nucleus expands devel.
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then.